An Observational Study on the Effect of Canagliflozin on Left Ventricular Diastolic Function in Patients with Type 2 Diabetes Mellitus in a Tertiary Care Hospital of West Bengal
Background: The incidence of type 2 diabetes mellitus (T2DM) is increasing in India. Left ventricular diastolic dysfunction (LVDD) is a complication of T2DM, which may develop irrespective of glycemic and hypertension control. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, e.g., empagliflozin an...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Jaypee Brothers Medical Publisher
2024-12-01
|
| Series: | Bengal Physician Journal |
| Subjects: | |
| Online Access: | https://www.apibpj.com/doi/BPJ/pdf/10.5005/jp-journals-10070-8056 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Background: The incidence of type 2 diabetes mellitus (T2DM) is increasing in India. Left ventricular diastolic dysfunction (LVDD) is a complication of T2DM, which may develop irrespective of glycemic and hypertension control. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, e.g., empagliflozin and canagliflozin have been shown to reduce all-cause mortality including cardiovascular mortality in T2DM patients.
Aims and objectives: The aims of this study were to evaluate the effect of canagliflozin on cardiac and renal parameters and improvement of LVDD at the end of 6 months in T2DM patients.
Materials and methods: About 100 T2DM patients meeting inclusion and exclusion criteria were put on Canagliflozin (100 mg/day) and followed up for 6 months. Clinicodemographic profiles with blood pressure (BP) and body mass index (BMI) and fasting blood sugar, HbA1c, serum creatinine, eGFR, urine albumin/creatinine ratio (UACR) were assessed at baseline and 6 months. Also, echocardiographic parameters like average E/e’, septal and lateral e’ velocity, TR velocity and LA volume index (LAVI) were assessed and statistically analysis by SPSS 22.0 software.
Results: Majority of patients were male (56%), aged between 45 and 60 years (57%), and obese (51%). Significant findings were, (1) Canagliflozin for 6 months improved E/A in 60 years and LAVI in <45 years’ age-group. (2) It improved LAVI in hypertensives and patients of <10 years of disease duration. (3) It improved serum creatinine and UACR. |
|---|---|
| ISSN: | 2582-1202 |